Price movement over the last 24 hours
ADMA Biologics Inc vs GE Aerospace — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while GE Aerospace trades at $356.45 (market cap $382.88B). The key difference: GE Aerospace is far larger — about 179.8× ADMA Biologics Inc's market cap, and GE Aerospace pays a 0.51% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GE | |
|---|---|---|
Market Cap | $2.13B | $382.88B |
Sector | Health | Industrials |
52-Week High | $20.38 | $378.68 |
52-Week Low | $7.60 | $247.05 |
Enterprise Value | $2.20B | $392.18B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GE trades at $378.68, up 0.31% today, with a bullish technical signal from moving averages and strong support at $375. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.86 exceeding expectations. Revenue grew to $45.86 billion in 2025, while net income margin improved to 17.86%. Recent news highlights robust order growth in aerospace and defense contracts, including a U.S. Air Force engine development deal announced May 19, 2026.
Outlook remains positive with a consensus price target of $394.33, though high valuation ratios (P/E 47.04) and rising debt levels pose risks. Aerospace demand and defense contracts support growth, but investors should monitor execution on expansion investments and macroeconomic pressures on aviation.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →